We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NIH to Decide Whether to Use ‘March-in Rights’ to Cut Cost of Prostate Cancer Drug
NIH to Decide Whether to Use ‘March-in Rights’ to Cut Cost of Prostate Cancer Drug
The National Institutes of Health (NIH) will decide this month whether Pfizer’s patent on Xtandi (enzalutamide), a prostate cancer drug’s that’s five times pricier in the U.S. than it is in other countries, is subject to so-called “march-in rights.”